Table 2.
The Nrf2 and ferroptosis interaction in cancer
| Molecular profile | Remark | Ref |
|---|---|---|
| HIF-1α/IRP1/TFR1 and Keap1/Nrf2/GPX4 | Trabectedin stimulates ferroptosis in lung cancer through suppressing Nrf2/GPX4 and upregulation of TFR1 | [105] |
| Nrf2/HO-1 | Nrf2/HO-1 suppression by ginkgetin to stimulate ferroptosis in lung cancer | [106] |
| AMPK/Nrf2/HMOX1 | AMPK/Nrf2/HMOX1 stimulation by vitamin C to accelerate ferroptosis in pancreatic cancer | [107] |
| P62/Keap1/Nrf2 | Metformin and sorafenib combination stimulates ferroptosis in hepatocellular carcinoma through Nrf2 downregulation | [108] |
| Keap1/Nrf2/HO-1 | Ferroptosis induction and stimulation of Keap1/Nrf2 suppress EMT in gastric cancer | [109] |
| P62/Keap1/Nrf2 | L-selenocystine’s ability to inhibit Nrf2 and autophagy, along with its effect on the p62-Keap-1-Nrf2 axis, leads to the selective death of Nrf2-dependent colorectal cancer cells | [110] |
| Nrf2 | The efficacy of phototherapy in tumor suppression increases by Nrf2 suppression and ferroptosis induction | [111] |
| GSK3β/Nrf2 | Silenced GSK3β increases Nrf2 expression to suppress ferroptosis in breast cancer | [112] |
| miR-365a-3p/NRF2 | MT1DP loaded by folate-modified liposomes makes non-small cell lung cancer cells more sensitive to the effects of erastin-induced ferroptosis via modulating the miR-365a-3p/NRF2 axis | [113] |
| CAMKK2 | CAMKK2 increases Nrf2 expression to suppress ferroptosis in melanoma | [114] |
| IGF2BP3/Nrf2 | IGF2BP3 increases Nrf2 stability to suppress ferroptosis in hepatocellular carcinoma | [115] |
| Nrf2 | Impairing the function of Nrf2 can increase ferroptosis in hepatocellular carcinoma | [116] |
| Nrf2/xCT | AdipoR1 suppresses Nrf2/xCT axis to enhance ferroptosis in hepatocellular carcinoma | [117] |
| VEGFR2/Nrf2 | Apatinib suppresses VEGFR2/Nrf2 to induce ferroptosis in glioma | [118] |
| Nrf2 | Pizotifen suppresses Nrf2 to increase ferroptosis in esophageal cancer | [119] |
| Nrf2/HO-1 | Nrf2/HO-1 downregulation by metformin in ferroptosis induction | [120] |
| Nrf2 | Oxaliplatin downregulates Nrf2 to increase oxidative damage and ferroptosis | [121] |
| Nrf2 | Increased degradation of Nrf2 by lysionotin in ferroptosis induction | [122] |
| Nrf2/GPX4 | Nrf2/GPX4 suppression by wogonin to induce ferroptosis in pancreatic cancer | [123] |
| Nrf2 | Nrf2 downregulation by ibrutinib to mediate ferroptosis in colorectal cancer | [124] |
| NRF2/HO-1 | NRF2/HO-1 downregulation by norcantharidin to stimulate ferroptosis in ovarian cancer | [125] |
| Nrf2/HO-1 | Nrf2/HO-1 stimulation by levistilide a to mediate fgerroptosis in breast cancer | [126] |
| Nrf2/GPX4 | AGuIX nanostructures suppress Nrf2/GPX4 axis to increase ferroptosis in cancer | [127] |
| Stat3/p53/NRF2 | Ginsenoside Rh3 downregulates Nrf2 to accelerate ferroptosis in colorectal cancer | [128] |
| Nrf2/HO-1/NQO1 | Eriodictyol suppresses Nrf2/HO-1/NQO1 to mediate ferroptosis and mitochondrial dysfunction in ovarian cancer | [129] |
| SIRT6/Nrf2/GPX4 | Isoorientin suppresses SIRT6/Nrf2/GPX4 axis to enhance ferroptosis in lung cancer | [130] |
| Nrf2/HO-1 | Acetaminophen suppresses Nrf2/HO-1 axis to induce ferroptosis in lung cancer | [131] |